Fig. 5.

Inhibition of CK2 results in decreased EGFR expression and combination therapies targeting CK2 and EGFR provide optimal response. a–b Xenografts X456 and X6 were treated with CX-4945 (10 μM) for 24 h, and expression of EGFR assessed by qPCR (n = 3). c Xenograft X6 was simultaneously treated with graded concentrations of CX-4945 and gefitinib for 96 h, and cell survival was assessed using the WST-1 assay (n = 3). *p < 0.05